Pfizer (PFE) Income from Discontinued Operations (2009 - 2026)

Pfizer (PFE) has reported Income from Discontinued Operations for 18 consecutive years, with $8.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Discontinued Operations fell 68.0% year-over-year to $8.0 million in Q2 2026; TTM through Jun 2026 was -$5.0 million, a 114.71% decrease from a year earlier, with the FY2025 full-year figure at $25.0 million, up 127.27% from the prior year.
• Income from Discontinued Operations was $8.0 million for Q2 2026 at Pfizer, up from -$13.0 million in the prior quarter.
• Over five years, Income from Discontinued Operations peaked at $34.0 million in Q3 2022 and troughed at -$26.0 million in Q4 2023.
• A 5-year average of $2.0 million and a median of -$2.0 million in 2023 frame the typical range for Income from Discontinued Operations.
• Across the five-year window, Income from Discontinued Operations tumbled 1000.0% in 2022 and surged 950.0% in 2024, its largest moves.
• Over 5 years, Income from Discontinued Operations stood at $34.0 million in 2022, then plunged by 176.47% to -$26.0 million in 2023, then surged by 69.23% to -$8.0 million in 2024, then soared by 412.5% to $25.0 million in 2025, then tumbled by 68.0% to $8.0 million in 2026.
• The last three Income from Discontinued Operations figures came in at $8.0 million (Q2 2026), -$13.0 million (Q1 2026), and $25.0 million (Q2 2025), per Business Quant data.